FY2026 Earnings Estimate for ACAD Issued By Leerink Partnrs

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Leerink Partnrs increased their FY2026 EPS estimates for shares of ACADIA Pharmaceuticals in a report issued on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of $1.15 per share for the year, up from their prior forecast of $1.09. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.51 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.35 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06. The firm had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 27.29%. The business’s quarterly revenue was up 18.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.40) EPS.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald lowered their price objective on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Royal Bank of Canada lowered their price objective on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 13th. Finally, Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $25.56.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $17.93 on Monday. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 22.99 and a beta of 0.38. ACADIA Pharmaceuticals has a fifty-two week low of $14.15 and a fifty-two week high of $32.59. The firm has a 50 day moving average price of $15.51 and a 200-day moving average price of $15.99.

Institutional Trading of ACADIA Pharmaceuticals

Several institutional investors have recently bought and sold shares of ACAD. Park Place Capital Corp purchased a new stake in ACADIA Pharmaceuticals during the 3rd quarter valued at about $25,000. Values First Advisors Inc. bought a new position in ACADIA Pharmaceuticals during the 3rd quarter valued at about $27,000. Covestor Ltd lifted its stake in ACADIA Pharmaceuticals by 70.5% during the 1st quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 840 shares during the period. Headlands Technologies LLC bought a new position in ACADIA Pharmaceuticals during the 1st quarter valued at about $48,000. Finally, Quest Partners LLC lifted its stake in ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares during the period. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ACADIA Pharmaceuticals

In other news, CEO Stephen Davis sold 31,747 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $485,094.16. Following the sale, the chief executive officer now directly owns 186,555 shares of the company’s stock, valued at $2,850,560.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Mark C. Schneyer sold 9,733 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $148,720.24. Following the sale, the chief financial officer now directly owns 43,735 shares of the company’s stock, valued at approximately $668,270.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen Davis sold 31,747 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $485,094.16. Following the sale, the chief executive officer now directly owns 186,555 shares in the company, valued at $2,850,560.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,014 shares of company stock valued at $779,494 in the last three months. 28.30% of the stock is currently owned by company insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.